Celltrion Sees Little Threat From ‘Overheated’ Biosimilar Competition

Presenting Q2 Results, Korean Giant Questions Ability Of Smaller Players To Survive

15 Aug 2024

Celltrion shrugged off challenges from smaller biosimilars players, calling out “overheated competition from new entrants” as it delivered its results and strategic developments for the second quarter of 2024, including pipeline updates paving the way for trials for its proposed Keytruda and Cosentyx biosimilars.

Small crowd of wooden figures next to large red wooden figure — Celltrion believes smaller biosimilars players will struggle to compete with larger outfits • Source: Shutterstock

Celltrion Sees Little Threat From ‘Overheated’ Biosimilar Competition

Presenting Q2 Results, Korean Giant Questions Ability Of Smaller Players To Survive

More from Biosimilars

More from Products